8-K: bioAffinity CyPath Lung Case Study Boosts Diagnostic Confidence

bioAffinity Technologies announced a new clinical case study demonstrating CyPath Lung's ability to provide actionable results and help patients avoid invasive procedures.

Summary

• bioAffinity Technologies released a new clinical case study for CyPath Lung, a noninvasive lung cancer test.
• The case study involved a 71-year-old high-risk patient with multiple pulmonary nodules, including one measuring 7 millimeters (mm).
• CyPath Lung's 'Unlikely Malignancy' result supported the physician's decision to defer an invasive lung biopsy.
• A follow-up CT scan in October 2025 showed the suspicious nodules had resolved, indicating benign inflammation, while another small nodule remained unchanged.
• CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in a clinical study for detecting lung cancer in small indeterminate nodules less than 20 millimeters.
• The test utilizes advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that may indicate malignancy.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, showcasing the real-world utility and benefits of CyPath Lung, which could enhance market adoption and investor confidence.

Positives

• CyPath Lung provides actionable results, improving diagnostic clarity for patients with multiple lung nodules.
• Helps patients avoid costly, invasive, and often risky procedures like bronchoscopy or biopsy when they are not necessary.
• Reduces patient anxiety by providing a clear indication of a low likelihood of malignancy.
• Supports physician decision-making in pulmonary nodule management.
• Demonstrated high performance in a clinical study with 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in small nodules (<20mm).
• The case study showed suspicious nodules resolving after a negative CyPath Lung result, indicating benign inflammation.

Risks

• The ability of CyPath Lung to accurately indicate the probability of lung cancer.
• The ability of CyPath Lung to provide confidence in a proposed course of action for high-risk patients.
• The ability of CyPath Lung to definitively determine if cancer is present or if the patient is cancer-free.
• The ability of CyPath Lung to effectively lower healthcare costs.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.

Future Outlook

The company believes CyPath Lung can indicate the probability of lung cancer, provide confidence in patient management, determine cancer presence, and lower healthcare costs. However, these forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations.

Management Comments

• "Multiple small nodules in a high-risk patient pose a diagnostic challenge, which can be exacerbated by the patient's understandable anxiety about a potential cancer." Daya Nadarajah, MD, patient's pulmonologist.
• "In this case, the patient's CyPath Lung result was negative, indicating a low likelihood of malignancy, and together both the patient and I were comfortable in waiting for a follow-up CT scan in three months." Daya Nadarajah, MD.
• "This is another patient case study that illustrates how CyPath Lung provides accurate results and greater confidence in pulmonary nodule management, supporting physician decision-making, reducing patient anxiety, and lowering healthcare costs by avoiding expensive, invasive and often risky procedures when they are not necessary." Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies.

Industry Context

StockSavvy.ai notes that the release of a positive clinical case study for CyPath Lung positions bioAffinity Technologies favorably within the competitive landscape of noninvasive cancer diagnostics. The emphasis on avoiding invasive procedures and reducing healthcare costs aligns with broader industry trends towards less intrusive and more cost-effective diagnostic solutions, particularly for high-risk populations. This could enhance the company's market penetration against traditional diagnostic methods.

Comparison to Industry Standards

• CyPath Lung's reported 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in small nodules (<20mm) compares favorably to other non-invasive lung cancer screening methods, which often struggle with high false-positive rates or lower sensitivity in early stages.
• The ability to avoid invasive procedures like bronchoscopy or biopsy, which carry risks of complications and significant costs, positions CyPath Lung as a potentially superior option for initial diagnostic clarity compared to current standard-of-care pathways that often lead directly to such procedures for indeterminate nodules.
• While specific comparable companies or projects are not named in the filing, the focus on reducing patient anxiety and healthcare costs through a non-invasive, AI-powered sputum test addresses a critical unmet need in lung cancer diagnostics, a space where companies like Guardant Health (liquid biopsy) and Veracyte (genomic classifiers) are also innovating but often with different sample types or methodologies.

Stakeholder Impact

• Shareholders: Positive impact due to validation of a key product, potentially leading to increased market confidence and future revenue.
• Patients: Significant positive impact by offering a noninvasive option that reduces anxiety, avoids painful and risky procedures, and lowers out-of-pocket costs.
• Healthcare Providers: Provides a valuable tool for improved diagnostic clarity and decision-making in managing high-risk patients with pulmonary nodules.
• Healthcare System: Potential for reduced overall healthcare costs by minimizing unnecessary invasive procedures.

Key Dates

Recommendation

The positive clinical case study provides strong validation for CyPath Lung's efficacy and practical benefits, such as avoiding invasive procedures and reducing patient anxiety. This real-world evidence, coupled with previously reported high sensitivity and specificity, significantly de-risks the product's market adoption potential. For a biotechnology company, such clinical validation is a critical catalyst for growth and could lead to increased investor confidence and a higher valuation.

Keywords

CyPath Lung, lung cancer, noninvasive diagnostic, biotechnology, pulmonary nodules, early detection, AI diagnostics, flow cytometry, medical technology, bioAffinity Technologies